- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for.
- The New England Journal of Medicine Research & Review.
- COX-2 inhibitor - pedia
- GLAVMEDINFO / The new england journal of medicine
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for.
Aproxen (PRECISION) demonstrated similar rates of cardiovascular risk in patients treated with prescription doses of celecoxib, ibuprofen and naproxen who had a clinical diagnosis of osteoarthritis (OA) or rheumatoid arthritis (RA), were at hh risk for cardiovascular disease, and required daily treatment with non-steroidal anti-inflammatory drugs (NSAIDs) to control symptoms of arthritis.
The New England Journal of Medicine Research & Review.
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.
COX-2 inhibitor - pedia
NEW ORLEANS -- After 10 years during which 24,000 osteoarthritis (OA) and rheumatoid arthritis (RA) patients were randomized, the verdict on cardiovascular safety of NSAIDs is in and it's not all that surprising: celecoxib (Celebrex) is no more likely to cause heart attacks or stroke than naproxen or ibuprofen.
GLAVMEDINFO / The new england journal of medicine
In fact the surprise in the long-awaited PRECISION study was not about the cardiovascular safety of the selective cyclooxygenase-2 (COX-2) inhibitor, but rather about the non-selective agent: naproxen.
New england journal of medicine celebrex:
Rating: 87 / 100
Overall: 87 Rates